Trump Reaches Agreement with Regeneron: 17th Pharmaceutical Agreement Since Autumn
Trump Announces Deal for Regeneron’s Drug Pricing WASHINGTON—President Donald Trump has revealed a new agreement that will implement most-favored-nation pricing for Regeneron’s latest medication within state Medicaid systems. This marks the 17th such deal he has established with a major pharmaceutical company since earlier this fall. A fact sheet from the White House outlines that […]
Trump reveals agreement with Regeneron Pharmaceuticals to lower medication costs
Trump Announces Drug Cost Reduction Deal with Regeneron On April 23, 2026, President Donald Trump revealed a significant agreement with Regeneron Pharmaceuticals aimed at lowering drug prices. This initiative is a key part of the administration’s broader effort to tackle drug pricing, which has been a major focus during his presidency. According to the announcement, […]
23andMe, once a favorite in Silicon Valley, bought by Regeneron Pharmaceuticals
Regeneron Pharmaceuticals to Acquire 23AndMe for $256 Million Regeneron Pharmaceuticals has announced its intent to purchase the bankrupt genetic testing company 23AndMe for $256 million. This move presents a chance for Regeneron to obtain a wealth of genetic samples and data, including details from over 15 million customers. However, this acquisition has sparked concerns among […]
Regeneron Pharmaceuticals is set to purchase 23andMe and its genetic information for $256 million.
Regeneron Pharmaceuticals to Acquire 23andMe from Bankruptcy Regeneron Pharmaceuticals announced on Monday its intention to purchase 23andMe for $256 million as the company emerges from bankruptcy. This acquisition includes 23andMe’s personal genomic service, Total Health and Research Services, along with a substantial biobank that holds genetic data from over 15 million customers. All genetic testing […]
Regeneron plans to acquire nearly all of 23andMe’s assets for $256 million.
Regeneron Acquires 23andMe Assets Amid Bankruptcy Regeneron Pharmaceuticals has declared its intention to acquire nearly all of the assets belonging to 23andMe, a genetic testing firm, following a court-supervised auction. The company has agreed to pay $256 million for these assets, with the auction occurring as part of 23andMe’s Chapter 11 bankruptcy protection filing from […]